Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.
“I am delighted to welcome Monica and Reno. They both bring an outstanding leadership to progress Egle towards a rich proprietary pipeline and the development of our therapeutic assets,” said Vincent Brichard, MD, PhD, Egle’s Interim CEO and Board member.
“I'm excited to join Egle Therapeutics to help develop novel immunotherapies targeting T regulatory cells for oncology and autoimmune diseases. I have been deeply impressed by the commitment of Egle’s staff, scientists, management, Board of Directors and Investors to advancing its groundbreaking science. With all developments accomplished so far, and together with the talented people we have, I am confident that we will deliver highly successful and much needed therapeutic options for patients in the years ahead,” said Monica Gostissa, CSO at Egle Therapeutics. As CSO, Dr. Gostissa will be responsible for all research, early development and translational activities.
“I am happy to be part of Egle Therapeutics’ leadership team to contribute my expertise in CMC and beyond to the company’s mission. I am truly enthusiastic about turning bold ideas into life-changing treatments, to innovate, and support creating new therapies. Excited for the journey ahead, I am ready to collaborate with a team that shares a common vision of making a significant impact on patients’ lives,” said Reno Winter, CTO at Egle Therapeutics. As CTO, Dr. Winter will be responsible for all manufacturing activities.
Dr. Gostissa has led preclinical programs at small and large biotech companies, focusing on how to best translate scientific insights into innovative cancer therapeutics. Most recently, she was Vice President of Preclinical Sciences at Jounce Therapeutics, where she contributed to establish the company’s scientific strategy and to oversee a broad preclinical portfolio of immuno-modulatory antibodies.
During her time at Jounce, Dr. Gostissa led efforts that enabled two IND applications, was involved in a successful outlicensing deal, and established and grew effective multi-disciplinary teams. Before starting her career in biotech, Dr. Gostissa spent many years in academic research, where she acquired a deep knowledge in cell biology, oncology and tumor immunology. Dr. Gostissa obtained her PhD in molecular genetics from the International School for Advanced Studies in Trieste, Italy, and completed post-doctoral studies at Boston Children's Hospital/Harvard Medical School. She co‑authored over 40 peer-reviewed publications and was the recipient of several awards, including a Leukemia and Lymphoma Society Special Fellow Award and a V Foundation Scholar Award.
Dr. Winter provides more than 10 years of experience in operationally leading and managing analytical & process development and external manufacturing activities. His expertise ranges from cell bank generation to drug substance and drug product manufacturing and supply.
Dr. Winter joined Egle Therapeutics in 2023, and assumes responsibility for the design, the establishment, and management of the manufacturing and supply strategy, as well as for the implementation of internal requirements and procedures to comply with applicable quality-related regulations and guidelines.
Previously, Dr. Winter worked as Head of CMC for a clinical-stage biotech company in Germany and as CMC Lead for Baxter/Shire PLC in Austria on numerous Investigational New Drug programs. In his past roles, he headed different teams to deliver and master all clinical trial-enabling CMC activities and actively contributed to numerous clinical trial applications and patents.
Dr. Winter is a trained biochemist and received his PhD in Natural Sciences from the Martin Luther University Halle-Wittenberg, Germany.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle ambition to advance toward the clinic its most advanced drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently developed in IND-enabling studies.
Find out more at www.egle-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327564913/en/
Contact information
contact@egle-tx.com / 0033 (0)1 86 64 08 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Video Distribution Patent Pool Gains Further Momentum with the Signing of Alibaba, ZTE, and Youku12.8.2025 03:00:00 EEST | Press release
Access Advance LLC today announced that Alibaba Group and ZTE Corporation have joined the Video Distribution Patent ("VDP") Pool as Licensors and Alibaba Group’s subsidiary Youku, one of China's leading video streaming platforms, has joined as a Licensee. The participation of these industry leaders strengthens the VDP Pool's comprehensive licensing solution by adding extensive patent portfolios, including significant contributions to both the HEVC/H.265 and the VVC/H.266 standard, while expanding coverage to Youku's massive user base. "We're delighted to welcome Alibaba, ZTE and Youku to the VDP Pool," said Peter Moller, CEO of Access Advance. "The addition of Alibaba and ZTE as Licensors brings critical intellectual property assets to the VDP Pool, while Youku's participation as a Licensee demonstrates the value of the pool's flexibility, predictable cost model, and simplified administration for major streaming platforms. They join other technology leaders including ByteDance, Kuaisho
First Cessna SkyCourier in Mongolia to Join Hunnu Air Fleet, Enhancing Operations in Asia-Pacific Region11.8.2025 17:00:00 EEST | Press release
The Cessna SkyCourier is making its entry into Mongolia with charter operator Hunnu Air placing the first order for the versatile twin-engine turboprop aircraft in the country. Hunnu Air will use the Cessna SkyCourier to enhance domestic tourism and cargo operations within Mongolia. The order includes two passenger variants of the Cessna SkyCourier aircraft and one Cessna Grand Caravan EX, with deliveries of their new aircraft expected to begin in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811928514/en/ First Cessna SkyCourier in Mongolia to join Hunnu Air fleet, enhancing operations in Asia-Pacific region (Photo Credit: Textron Aviation) The Cessna SkyCourier is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. "Designed for versatility and performance, the Cessna SkyCourier is a strong fit to support Hunnu Air’s services across Mongolia,” said Lannie O’Bannion, senior vice pres
84% of Consumers Would Switch Banks Over Financial Crime Links, ThetaRay Report Finds11.8.2025 17:00:00 EEST | Press release
ThetaRay, a global leader in Cognitive AI financial crime compliance, today released its U.S. Banking & Fintech Trust Report 2025, offering new insights into consumer attitudes toward anti-money laundering (AML) practices. The report reveals that 84% of consumers would switch banks if linked to financial crime, and 87% would actively warn family and friends against using that institution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811009362/en/ Brand reputation is one of a financial institution’s most valuable and vulnerable assets, built over years through trust, consistency, and significant investment. Encouragingly, 93% of respondents express either positive or neutral sentiments toward their current financial providers, suggesting a strong foundation of customer trust. But that trust is fragile: a single incident of financial crime can shatter a reputation overnight, triggering customer attrition, regulatory penal
Andersen Consulting Adds Endeavor Management, Expanding Its Strategy and Business Transformation Capabilities11.8.2025 16:30:00 EEST | Press release
Andersen Consulting expands its strategy and transformation capabilities with the addition of new member Endeavor Management, a management consultancy with a six-decade legacy of helping complex organizations align, transform, and grow. Endeavor Management and its full-service embedded advertising agency, RTRN Strategy, have earned a national reputation for activating change where it matters most: at the intersection of brand, culture, and operations. With particular depth in the healthcare and energy sectors, the firm brings specialized experience helping organizations navigate high-stakes transformation in highly regulated and rapidly evolving environments. Endeavor’s expertise in enterprise transformation, brand alignment, and growth strategy further strengthens Andersen Consulting’s ability to deliver end-to-end consulting solutions that are insight-driven, execution-focused, and globally scalable. Endeavor Management will begin its transition to the Andersen Consulting brand in th
Ant International Partners with Abu Dhabi Investment Office and Receives IPA from Central Bank of the UAE to Support Local Digitalisation and Fintech Strategy11.8.2025 15:16:00 EEST | Press release
Ant International, a leading global digital payment, digitisation and financial technology provider, today announces two milestones that mark a significant step forward for its business expansion in the United Arab Emirates (UAE). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811794890/en/ Pictured here H.E. Badr Al-Olama, Director General of Abu Dhabi Investment Office, and Peng Yang, CEO of Ant International, commemorate the signing of a MoU to promote deeper collaboration in Abu Dhabi. It has signed a Memorandum of Understanding (MoU) with the Abu Dhabi Investment Office (ADIO) and received In-Principle Approval (IPA) for the Stored Value Facilities (SVF) and the Retail Payment Services and Card Schemes (RPSCS) licenses from the Central Bank of the UAE (CBUAE). These developments underscore Ant International's commitment to supporting the Central Bank’s digital transformation agenda and contributing to the UAE’s finte
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom